The Power of Long-term Data in Anti-IL-5 Choice
Hall 3, Altice Arena
Agenda
Different MoA translates in different efficacy
Ana Todo Bom, Portugal
Nota biográfica disponível aqui
Mepolizumab: The evidence of lasting efficacy & safety to support clinician’s choice
Emilio Pizzichini, Brazil
Nota biográfica disponível aqui
Clinician‘s perspectives: The long-term experience with Mepolizumab
Stefan Cimbollek, Spain
Nota biográfica disponível aqui